[
  {
    "question": {
      "question_id": "cs03_q11_longitudinal",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 20,
      "question_type": "longitudinal",
      "prompt": "What is the emerging safety profile of LNS-4821, and which patient subgroup is most affected?",
      "ground_truth": {
        "canonical_answer": "Hepatotoxicity in the statin co-administered subgroup. ALT elevations reaching 2-3x ULN across multiple sites, with two subjects meeting Hy's Law criteria. Non-statin patients remain stable. The cross-site distribution rules out the Site 07 equipment hypothesis.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_017",
          "clinical_signal_03_ep_018",
          "clinical_signal_03_ep_019"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity",
          "Site 07 lab equipment issue is not the cause of ALT elevations",
          "the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns",
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event",
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q11_longitudinal",
      "answer_text": "The provided documents do not contain specific information about the emerging safety profile of LNS-4821 or the patient subgroup most affected. While the documents include enrollment data and concomitant statin use across various sites and dates, they lack details on adverse events, safety signals, or subgroup analyses related to LNS-4821 [clinical_signal_03_ep_020][clinical_signal_03_ep_004][clinical_signal_03_ep_003][clinical_signal_03_ep_019][clinical_signal_03_ep_006][clinical_signal_03_ep_018][clinical_signal_03_ep_016]. Therefore, based on the available information, it is not possible to determine the safety profile or the most affected patient subgroup.",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_9af281f1b77c45739d90a96e",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 756
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_9af281f1b77c45739d90a96e",
              "content": "{\"search_modes\": [\"keyword\", \"semantic\"], \"filter_fields\": [{\"name\": \"scope_id\", \"field_type\": \"string\", \"description\": \"Filter by scope ID\", \"enum_values\": null}, {\"name\": \"start_date\", \"field_type\": \"string\", \"description\": \"Filter episodes after this ISO date\", \"enum_values\": null}, {\"name\": \"end_date\", \"field_type\": \"string\", \"description\": \"Filter episodes before this ISO date\", \"enum_values\": null}], \"max_results_per_search\": 7, \"supports_date_range\": true, \"extra_tools\": [{\"name\": \"batch_retrieve\", \"description\": \"Retrieve multiple full documents by their reference IDs in a single call. PREFER this over calling memory_retrieve multiple times \\u2014 it is far more efficient and uses only one tool call instead of one per document. After memory_search, pass all ref_ids you want to read to this tool.\", \"parameters\": {\"type\": \"object\", \"properties\": {\"ref_ids\": {\"type\": \"array\", \"items\": {\"type\": \"string\"}, \"description\": \"List of reference IDs to retrieve (from search results).\"}}, \"required\": [\"ref_ids\"]}}]}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_bece72bb27644a01bb067216",
              "name": "memory_search",
              "arguments": {
                "query": "LNS-4821 safety profile patient subgroup",
                "filters": {}
              }
            }
          ],
          "tokens_used": 1060
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_bece72bb27644a01bb067216",
              "content": "[{\"ref_id\": \"clinical_signal_03_ep_020\", \"text\": \"## 2024-07-15 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 216\\n- Active: 206\\n- Screen Failures Cumulative: 45\\n- Withdrawals Cumulative: 10\\n\\n#### Sites\\n- Site 01 Enrolled: 22\\n- Site 01 Active: 22\\n- Site 01 Statin Concomitant: 7\\n- Site 02 Enrolled: 16\\n- Site 02 Active: 16\\n- Site 02 Statin Concomitant: 5\\n- Site 03 Enrolled: 20\\n- Site 03 Active: 20\\n- Site 03 Statin Concomitant: 6\\n- Site 04 Enrolled: 14\\n- Site 04 Active: 14\\n- Site 04 Statin Concomitant: 4\\n- Site 05 Enrolled: 18\\n- Site\", \"score\": 0.03278688524590164, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"escalation\", \"signal_density\": \"high\"}}, {\"ref_id\": \"clinical_signal_03_ep_004\", \"text\": \"## 2024-03-25 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 100\\n- Active: 98\\n- Screen Failures Cumulative: 11\\n- Withdrawals Cumulative: 2\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 10\\n  - Active: 10\\n  - Statin Concomitant: 2\\n- Site 02\\n  - Enrolled: 7\\n  - Active: 7\\n  - Statin Concomitant: 1\\n- Site 03\\n  - Enrolled: 9\\n  - Active: 9\\n  - Statin Concomitant: 2\\n- Site 04\\n  - Enrolled: 6\\n  - Active: 6\\n  - Statin Concomitant: 1\\n- Site 05\\n  - Enrolled: 8\\n  - Active: 8\\n  - Statin Concomitant: 2\\n- S\", \"score\": 0.0315136476426799, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_003\", \"text\": \"## 2024-03-18 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 80\\n- Active: 80\\n- Screen Failures Cumulative: 5\\n- Withdrawals Cumulative: 0\\n\\n#### Sites\\n- Site 01 Enrolled: 8\\n- Site 01 Active: 8\\n- Site 01 Statin Concomitant: 2\\n- Site 02 Enrolled: 6\\n- Site 02 Active: 6\\n- Site 02 Statin Concomitant: 1\\n- Site 03 Enrolled: 7\\n- Site 03 Active: 7\\n- Site 03 Statin Concomitant: 1\\n- Site 04 Enrolled: 5\\n- Site 04 Active: 5\\n- Site 04 Statin Concomitant: 1\\n- Site 05 Enrolled: 6\\n- Site 05 Active: 6\", \"score\": 0.030776515151515152, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_019\", \"text\": \"## 2024-07-08 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 202\\n- Active: 196\\n- Screen Failures Cumulative: 37\\n- Withdrawals Cumulative: 6\\n\\n### Sites\\n- Site 01\\n  - Enrolled: 20\\n  - Active: 20\\n  - Statin Concomitant: 6\\n- Site 02\\n  - Enrolled: 15\\n  - Active: 15\\n  - Statin Concomitant: 3\\n- Site 03\\n  - Enrolled: 18\\n  - Active: 18\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 13\\n  - Active: 13\\n  - Statin Concomitant: 3\\n- Site 05\\n  - Enrolled: 17\\n  - Active: 17\\n  - Statin Concomitan\", \"score\": 0.030621785881252923, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"escalation\", \"signal_density\": \"high\"}}, {\"ref_id\": \"clinical_signal_03_ep_006\", \"text\": \"## 2024-04-08 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 140\\n- Active: 137\\n- Screen Failures Cumulative: 11\\n- Withdrawals Cumulative: 3\\n\\n#### Sites\\n- Site 01 Enrolled: 14\\n- Site 01 Active: 14\\n- Site 01 Statin Concomitant: 4\\n- Site 02 Enrolled: 10\\n- Site 02 Active: 10\\n- Site 02 Statin Concomitant: 3\\n- Site 03 Enrolled: 18\\n- Site 03 Active: 17\\n- Site 03 Statin Concomitant: 5\\n- Site 04 Enrolled: 9\\n- Site 04 Active: 9\\n- Site 04 Statin Concomitant: 2\\n- Site 05 Enrolled: 11\\n- Site 05\", \"score\": 0.03057889822595705, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_018\", \"text\": \"## 2024-07-01 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 210\\n- Active: 204\\n- Screen Failures Cumulative: 53\\n- Withdrawals Cumulative: 6\\n\\n#### Sites\\n- Site 01 Enrolled: 21\\n- Site 01 Active: 21\\n- Site 01 Statin Concomitant: 7\\n- Site 02 Enrolled: 16\\n- Site 02 Active: 16\\n- Site 02 Statin Concomitant: 4\\n- Site 03 Enrolled: 19\\n- Site 03 Active: 19\\n- Site 03 Statin Concomitant: 5\\n- Site 04 Enrolled: 14\\n- Site 04 Active: 14\\n- Site 04 Statin Concomitant: 4\\n- Site 05 Enrolled: 17\\n- Site \", \"score\": 0.030536130536130537, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"escalation\", \"signal_density\": \"high\"}}, {\"ref_id\": \"clinical_signal_03_ep_016\", \"text\": \"## 2024-06-17 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 204\\n- Active: 198\\n- Screen Failures Cumulative: 47\\n- Withdrawals Cumulative: 6\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 20\\n  - Active: 20\\n  - Statin Concomitant: 6\\n- Site 02\\n  - Enrolled: 15\\n  - Active: 15\\n  - Statin Concomitant: 4\\n- Site 03\\n  - Enrolled: 19\\n  - Active: 19\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 13\\n  - Active: 13\\n  - Statin Concomitant: 4\\n- Site 05\\n  - Enrolled: 17\\n  - Active: 17\\n  - Statin Concomita\", \"score\": 0.029910714285714284, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"red_herring\", \"signal_density\": \"medium\"}}]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_98f5d4cfa4384104b42902bc",
              "name": "batch_retrieve",
              "arguments": {
                "ref_ids": [
                  "clinical_signal_03_ep_020",
                  "clinical_signal_03_ep_004",
                  "clinical_signal_03_ep_003",
                  "clinical_signal_03_ep_019",
                  "clinical_signal_03_ep_006",
                  "clinical_signal_03_ep_018",
                  "clinical_signal_03_ep_016"
                ]
              }
            }
          ],
          "tokens_used": 3242
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_98f5d4cfa4384104b42902bc",
              "content": "[Context budget exhausted \u2014 synthesize answer from evidence already retrieved]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "The provided documents do not contain specific information about the emerging safety profile of LNS-4821 or the patient subgroup most affected. While the documents include enrollment data and concomitant statin use across various sites and dates, they lack details on adverse events, safety signals, or subgroup analyses related to LNS-4821 [clinical_signal_03_ep_020][clinical_signal_03_ep_004][clinical_signal_03_ep_003][clinical_signal_03_ep_019][clinical_signal_03_ep_006][clinical_signal_03_ep_018][clinical_signal_03_ep_016]. Therefore, based on the available information, it is not possible to determine the safety profile or the most affected patient subgroup.",
          "tokens_used": 3439
        }
      ],
      "tool_calls_made": 3,
      "total_tokens": 8497,
      "wall_time_ms": 11991.472452995367,
      "budget_violations": [
        "Cumulative result token limit exceeded: 8456 > 2048"
      ],
      "refs_cited": [
        "clinical_signal_03_ep_020",
        "clinical_signal_03_ep_004",
        "clinical_signal_03_ep_003",
        "clinical_signal_03_ep_019",
        "clinical_signal_03_ep_006",
        "clinical_signal_03_ep_018",
        "clinical_signal_03_ep_016"
      ]
    },
    "retrieved_ref_ids": [
      "clinical_signal_03_ep_020",
      "clinical_signal_03_ep_004",
      "clinical_signal_03_ep_003",
      "clinical_signal_03_ep_019",
      "clinical_signal_03_ep_006",
      "clinical_signal_03_ep_018",
      "clinical_signal_03_ep_016"
    ],
    "valid_ref_ids": [
      "clinical_signal_03_ep_020",
      "clinical_signal_03_ep_004",
      "clinical_signal_03_ep_003",
      "clinical_signal_03_ep_019",
      "clinical_signal_03_ep_006",
      "clinical_signal_03_ep_018",
      "clinical_signal_03_ep_016"
    ]
  },
  {
    "question": {
      "question_id": "cs03_q12_severity",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 20,
      "question_type": "severity_assessment",
      "prompt": "How would you assess the severity of the hepatic signal and the urgency of protocol intervention?",
      "ground_truth": {
        "canonical_answer": "High severity. Two subjects have met Hy's Law criteria (ALT >3x ULN + bilirubin >2x ULN), which is a recognized indicator of potential drug-induced liver injury. The signal is escalating and protocol amendment is urgent to prevent further SAEs.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_017",
          "clinical_signal_03_ep_019"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity",
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge",
          "the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns",
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "Site 07 lab equipment issue is not the cause of ALT elevations",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q12_severity",
      "answer_text": "The hepatic signal severity appears to escalate over time, with initial low signal density during the early signal phase (e.g., episodes clinical_signal_03_ep_009, clinical_signal_03_ep_010, clinical_signal_03_ep_011, clinical_signal_03_ep_013) [ref_id: clinical_signal_03_ep_009][ref_id: clinical_signal_03_ep_010][ref_id: clinical_signal_03_ep_011][ref_id: clinical_signal_03_ep_013]. By mid-study, the signal density increases to high levels during the escalation phase, as seen in clinical_signal_03_ep_017 and clinical_signal_03_ep_020, indicating a growing concern [ref_id: clinical_signal_03_ep_017][ref_id: clinical_signal_03_ep_020].\n\nAlthough specific hepatic lab values or clinical events are not detailed in the retrieved summaries, the shift from low to high signal density suggests an increasing severity of the hepatic signal. This progression implies a rising urgency for protocol intervention, particularly during the escalation phase, to evaluate potential drug-induced liver injury and consider risk mitigation strategies such as enhanced monitoring, dose adjustments, or exclusion of high-risk patients [ref_id: clinical_signal_03_ep_017][ref_id: clinical_signal_03_ep_020].",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_90461c8c204444a38b1e2a88",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 751
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_90461c8c204444a38b1e2a88",
              "content": "{\"search_modes\": [\"keyword\", \"semantic\"], \"filter_fields\": [{\"name\": \"scope_id\", \"field_type\": \"string\", \"description\": \"Filter by scope ID\", \"enum_values\": null}, {\"name\": \"start_date\", \"field_type\": \"string\", \"description\": \"Filter episodes after this ISO date\", \"enum_values\": null}, {\"name\": \"end_date\", \"field_type\": \"string\", \"description\": \"Filter episodes before this ISO date\", \"enum_values\": null}], \"max_results_per_search\": 7, \"supports_date_range\": true, \"extra_tools\": [{\"name\": \"batch_retrieve\", \"description\": \"Retrieve multiple full documents by their reference IDs in a single call. PREFER this over calling memory_retrieve multiple times \\u2014 it is far more efficient and uses only one tool call instead of one per document. After memory_search, pass all ref_ids you want to read to this tool.\", \"parameters\": {\"type\": \"object\", \"properties\": {\"ref_ids\": {\"type\": \"array\", \"items\": {\"type\": \"string\"}, \"description\": \"List of reference IDs to retrieve (from search results).\"}}, \"required\": [\"ref_ids\"]}}]}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_2dd90cba047c4c80b780ff95",
              "name": "memory_search",
              "arguments": {
                "query": "hepatic signal severity assessment protocol intervention",
                "filters": {}
              }
            }
          ],
          "tokens_used": 1052
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_2dd90cba047c4c80b780ff95",
              "content": "[{\"ref_id\": \"clinical_signal_03_ep_009\", \"text\": \"## 2024-04-29 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 185\\n- Active: 180\\n- Screen Failures Cumulative: 22\\n- Withdrawals Cumulative: 5\\n\\n#### Sites\\n- Site 01 Enrolled: 18\\n- Site 01 Active: 18\\n- Site 01 Statin Concomitant: 5\\n- Site 02 Enrolled: 14\\n- Site 02 Active: 14\\n- Site 02 Statin Concomitant: 4\\n- Site 03 Enrolled: 17\\n- Site 03 Active: 17\\n- Site 03 Statin Concomitant: 4\\n- Site 04 Enrolled: 12\\n- Site 04 Active: 12\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 15\\n- Site \", \"score\": 0.031754032258064516, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_008\", \"text\": \"## 2024-04-22 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 180\\n- Active: 177\\n- Screen Failures Cumulative: 13\\n- Withdrawals Cumulative: 3\\n\\n#### Sites\\n- Site 01 Enrolled: 18\\n- Site 01 Active: 18\\n- Site 01 Statin Concomitant: 5\\n- Site 02 Enrolled: 13\\n- Site 02 Active: 13\\n- Site 02 Statin Concomitant: 3\\n- Site 03 Enrolled: 16\\n- Site 03 Active: 16\\n- Site 03 Statin Concomitant: 4\\n- Site 04 Enrolled: 12\\n- Site 04 Active: 12\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 15\\n- Site \", \"score\": 0.03055037313432836, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_010\", \"text\": \"## 2024-05-06 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 184\\n- Active: 182\\n- Screen Failures Cumulative: 20\\n- Withdrawals Cumulative: 2\\n\\n#### Sites\\n- Site 01 Enrolled: 18\\n- Site 01 Active: 18\\n- Site 01 Statin Concomitant: 5\\n- Site 02 Enrolled: 14\\n- Site 02 Active: 14\\n- Site 02 Statin Concomitant: 3\\n- Site 03 Enrolled: 17\\n- Site 03 Active: 17\\n- Site 03 Statin Concomitant: 4\\n- Site 04 Enrolled: 12\\n- Site 04 Active: 12\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 15\\n- Site \", \"score\": 0.0304147465437788, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_017\", \"text\": \"## 2024-06-24 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 225\\n- Active: 214\\n- Screen Failures Cumulative: 30\\n- Withdrawals Cumulative: 11\\n\\n#### Sites\\n- Site 01 Enrolled: 23\\n- Site 01 Active: 23\\n- Site 01 Statin Concomitant: 7\\n- Site 02 Enrolled: 17\\n- Site 02 Active: 17\\n- Site 02 Statin Concomitant: 5\\n- Site 03 Enrolled: 21\\n- Site 03 Active: 21\\n- Site 03 Statin Concomitant: 6\\n- Site 04 Enrolled: 15\\n- Site 04 Active: 15\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 19\\n- Site\", \"score\": 0.03036576949620428, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"escalation\", \"signal_density\": \"high\"}}, {\"ref_id\": \"clinical_signal_03_ep_011\", \"text\": \"## 2024-05-13 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 189\\n- Active: 182\\n- Screen Failures Cumulative: 27\\n- Withdrawals Cumulative: 7\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 19\\n  - Active: 19\\n  - Statin Concomitant: 5\\n- Site 02\\n  - Enrolled: 14\\n  - Active: 14\\n  - Statin Concomitant: 3\\n- Site 03\\n  - Enrolled: 17\\n  - Active: 17\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 12\\n  - Active: 12\\n  - Statin Concomitant: 3\\n- Site 05\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomita\", \"score\": 0.03036576949620428, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_013\", \"text\": \"## 2024-05-27 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 195\\n- Active: 191\\n- Screen Failures Cumulative: 29\\n- Withdrawals Cumulative: 4\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 19\\n  - Active: 19\\n  - Statin Concomitant: 5\\n- Site 02\\n  - Enrolled: 14\\n  - Active: 14\\n  - Statin Concomitant: 4\\n- Site 03\\n  - Enrolled: 18\\n  - Active: 18\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 13\\n  - Active: 13\\n  - Statin Concomitant: 4\\n- Site 05\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomita\", \"score\": 0.03028233151183971, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_020\", \"text\": \"## 2024-07-15 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 216\\n- Active: 206\\n- Screen Failures Cumulative: 45\\n- Withdrawals Cumulative: 10\\n\\n#### Sites\\n- Site 01 Enrolled: 22\\n- Site 01 Active: 22\\n- Site 01 Statin Concomitant: 7\\n- Site 02 Enrolled: 16\\n- Site 02 Active: 16\\n- Site 02 Statin Concomitant: 5\\n- Site 03 Enrolled: 20\\n- Site 03 Active: 20\\n- Site 03 Statin Concomitant: 6\\n- Site 04 Enrolled: 14\\n- Site 04 Active: 14\\n- Site 04 Statin Concomitant: 4\\n- Site 05 Enrolled: 18\\n- Site\", \"score\": 0.029906956136464335, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"escalation\", \"signal_density\": \"high\"}}]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_da62e8d2d9674edbaa641c97",
              "name": "batch_retrieve",
              "arguments": {
                "ref_ids": [
                  "clinical_signal_03_ep_009",
                  "clinical_signal_03_ep_008",
                  "clinical_signal_03_ep_010",
                  "clinical_signal_03_ep_017",
                  "clinical_signal_03_ep_011",
                  "clinical_signal_03_ep_013",
                  "clinical_signal_03_ep_020"
                ]
              }
            }
          ],
          "tokens_used": 3237
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_da62e8d2d9674edbaa641c97",
              "content": "[Context budget exhausted \u2014 synthesize answer from evidence already retrieved]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "The hepatic signal severity appears to escalate over time, with initial low signal density during the early signal phase (e.g., episodes clinical_signal_03_ep_009, clinical_signal_03_ep_010, clinical_signal_03_ep_011, clinical_signal_03_ep_013) [ref_id: clinical_signal_03_ep_009][ref_id: clinical_signal_03_ep_010][ref_id: clinical_signal_03_ep_011][ref_id: clinical_signal_03_ep_013]. By mid-study, the signal density increases to high levels during the escalation phase, as seen in clinical_signal_03_ep_017 and clinical_signal_03_ep_020, indicating a growing concern [ref_id: clinical_signal_03_ep_017][ref_id: clinical_signal_03_ep_020].\n\nAlthough specific hepatic lab values or clinical events are not detailed in the retrieved summaries, the shift from low to high signal density suggests an increasing severity of the hepatic signal. This progression implies a rising urgency for protocol intervention, particularly during the escalation phase, to evaluate potential drug-induced liver injury and consider risk mitigation strategies such as enhanced monitoring, dose adjustments, or exclusion of high-risk patients [ref_id: clinical_signal_03_ep_017][ref_id: clinical_signal_03_ep_020].",
          "tokens_used": 3571
        }
      ],
      "tool_calls_made": 3,
      "total_tokens": 8611,
      "wall_time_ms": 13792.706769076176,
      "budget_violations": [
        "Cumulative result token limit exceeded: 7849 > 2048"
      ],
      "refs_cited": []
    },
    "retrieved_ref_ids": [],
    "valid_ref_ids": []
  },
  {
    "question": {
      "question_id": "cs03_q15_negative",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 20,
      "question_type": "negative",
      "prompt": "Is there evidence of an immune-mediated reaction or immunogenicity issues with LNS-4821?",
      "ground_truth": {
        "canonical_answer": "No. Immunogenicity markers and antibody responses are not related to the hepatic safety signal. The mechanism is a pharmacokinetic drug-drug interaction via CYP3A4, not an immune-mediated reaction.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_005",
          "clinical_signal_03_ep_012"
        ],
        "key_facts": [
          "the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q15_negative",
      "answer_text": "Based on the available information, there is no evidence of immune-mediated reactions or immunogenicity issues with LNS-4821. The retrieved documents detail adverse events such as nasopharyngitis, insomnia, nausea, fatigue, and upper respiratory infections, but none of these are classified as immune-mediated, and no relatedness to immunogenicity has been reported [clinical_signal_03_ep_004][clinical_signal_03_ep_006][clinical_signal_03_ep_007]. Additionally, operational summaries do not mention any safety signals related to immune responses [clinical_signal_03_ep_020][clinical_signal_03_ep_017].",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_ba9c1e91b33444b08e63bbe0",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 755
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_ba9c1e91b33444b08e63bbe0",
              "content": "{\"search_modes\": [\"keyword\", \"semantic\"], \"filter_fields\": [{\"name\": \"scope_id\", \"field_type\": \"string\", \"description\": \"Filter by scope ID\", \"enum_values\": null}, {\"name\": \"start_date\", \"field_type\": \"string\", \"description\": \"Filter episodes after this ISO date\", \"enum_values\": null}, {\"name\": \"end_date\", \"field_type\": \"string\", \"description\": \"Filter episodes before this ISO date\", \"enum_values\": null}], \"max_results_per_search\": 7, \"supports_date_range\": true, \"extra_tools\": [{\"name\": \"batch_retrieve\", \"description\": \"Retrieve multiple full documents by their reference IDs in a single call. PREFER this over calling memory_retrieve multiple times \\u2014 it is far more efficient and uses only one tool call instead of one per document. After memory_search, pass all ref_ids you want to read to this tool.\", \"parameters\": {\"type\": \"object\", \"properties\": {\"ref_ids\": {\"type\": \"array\", \"items\": {\"type\": \"string\"}, \"description\": \"List of reference IDs to retrieve (from search results).\"}}, \"required\": [\"ref_ids\"]}}]}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_552bd953cb424439bc243366",
              "name": "memory_search",
              "arguments": {
                "query": "LNS-4821 immune-mediated reaction immunogenicity",
                "filters": {}
              }
            }
          ],
          "tokens_used": 1061
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_552bd953cb424439bc243366",
              "content": "[{\"ref_id\": \"clinical_signal_03_ep_020\", \"text\": \"## 2024-07-15 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 216\\n- Active: 206\\n- Screen Failures Cumulative: 45\\n- Withdrawals Cumulative: 10\\n\\n#### Sites\\n- Site 01 Enrolled: 22\\n- Site 01 Active: 22\\n- Site 01 Statin Concomitant: 7\\n- Site 02 Enrolled: 16\\n- Site 02 Active: 16\\n- Site 02 Statin Concomitant: 5\\n- Site 03 Enrolled: 20\\n- Site 03 Active: 20\\n- Site 03 Statin Concomitant: 6\\n- Site 04 Enrolled: 14\\n- Site 04 Active: 14\\n- Site 04 Statin Concomitant: 4\\n- Site 05 Enrolled: 18\\n- Site\", \"score\": 0.03278688524590164, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"escalation\", \"signal_density\": \"high\"}}, {\"ref_id\": \"clinical_signal_03_ep_004\", \"text\": \"## 2024-03-25 Daily Operations Summary\\n### Adverse Events\\n- AE ID: AE-0011, Description: nasopharyngitis, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\\n- AE ID: AE-0012, Description: insomnia, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: non_statin\", \"score\": 0.03225806451612903, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_006\", \"text\": \"## 2024-04-08 Daily Operations Summary\\n### Adverse Events\\n- AE ID: AE-0017, Description: nausea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\\n- AE ID: AE-0018, Description: fatigue, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: statin\\n- AE ID: AE-0019, Description: upper respiratory infection, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: statin\", \"score\": 0.03200204813108039, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_017\", \"text\": \"## 2024-06-24 Daily Operations Summary\\n### Investigator Notes\\n- Lab kits inventory adequate for next 4 weeks\\n- Enrollment on track per protocol timeline\\n- Site pharmacy inventory verified\", \"score\": 0.031754032258064516, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"escalation\", \"signal_density\": \"high\"}}, {\"ref_id\": \"clinical_signal_03_ep_003\", \"text\": \"## 2024-03-18 Daily Operations Summary\\n### Investigator Notes\\n- All CRFs current through prior visit cycle\\n- Query resolution rate at 94%\\n- Lab kits inventory adequate for next 4 weeks\", \"score\": 0.0315136476426799, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_007\", \"text\": \"## 2024-04-15 Daily Operations Summary\\n### Adverse Events\\n- AE ID: AE-0020, Description: upper respiratory infection, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\\n- AE ID: AE-0021, Description: insomnia, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: non_statin\\n- AE ID: AE-0022, Description: upper respiratory infection, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: statin\", \"score\": 0.03128054740957967, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_002\", \"text\": \"## 2024-03-11 Daily Operations Summary\\n### Investigator Notes\\n- Site pharmacy inventory verified\\n- Subject retention rate within protocol targets\\n- Study drug accountability reconciled, no discrepancies\", \"score\": 0.031054405392392875, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_8b19745059fc4014ad3a78e4",
              "name": "batch_retrieve",
              "arguments": {
                "ref_ids": [
                  "clinical_signal_03_ep_020",
                  "clinical_signal_03_ep_004",
                  "clinical_signal_03_ep_006",
                  "clinical_signal_03_ep_017",
                  "clinical_signal_03_ep_003",
                  "clinical_signal_03_ep_007",
                  "clinical_signal_03_ep_002"
                ]
              }
            }
          ],
          "tokens_used": 2400
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_8b19745059fc4014ad3a78e4",
              "content": "[Context budget exhausted \u2014 synthesize answer from evidence already retrieved]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "Based on the available information, there is no evidence of immune-mediated reactions or immunogenicity issues with LNS-4821. The retrieved documents detail adverse events such as nasopharyngitis, insomnia, nausea, fatigue, and upper respiratory infections, but none of these are classified as immune-mediated, and no relatedness to immunogenicity has been reported [clinical_signal_03_ep_004][clinical_signal_03_ep_006][clinical_signal_03_ep_007]. Additionally, operational summaries do not mention any safety signals related to immune responses [clinical_signal_03_ep_020][clinical_signal_03_ep_017].",
          "tokens_used": 2571
        }
      ],
      "tool_calls_made": 3,
      "total_tokens": 6787,
      "wall_time_ms": 10821.389485965483,
      "budget_violations": [
        "Cumulative result token limit exceeded: 7807 > 2048"
      ],
      "refs_cited": [
        "clinical_signal_03_ep_004",
        "clinical_signal_03_ep_006",
        "clinical_signal_03_ep_007",
        "clinical_signal_03_ep_020",
        "clinical_signal_03_ep_017"
      ]
    },
    "retrieved_ref_ids": [
      "clinical_signal_03_ep_004",
      "clinical_signal_03_ep_006",
      "clinical_signal_03_ep_007",
      "clinical_signal_03_ep_020",
      "clinical_signal_03_ep_017"
    ],
    "valid_ref_ids": [
      "clinical_signal_03_ep_004",
      "clinical_signal_03_ep_006",
      "clinical_signal_03_ep_007",
      "clinical_signal_03_ep_020",
      "clinical_signal_03_ep_017"
    ]
  },
  {
    "question": {
      "question_id": "cs03_q17_temporal",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 20,
      "question_type": "temporal",
      "prompt": "How rapidly are ALT values escalating in the affected subgroup?",
      "ground_truth": {
        "canonical_answer": "ALT values in the statin subgroup have progressed from baseline normal (15-35 U/L) through subtle elevation (45-65 U/L) to clinically significant levels (80-120 U/L, 2-3x ULN) over the course of the signal and escalation phases. The rate of increase has accelerated.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_017",
          "clinical_signal_03_ep_019"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event",
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge",
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "Site 07 lab equipment issue is not the cause of ALT elevations",
          "the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q17_temporal",
      "answer_text": "The provided documents do not contain specific data on the rate of ALT value escalation in the affected subgroup. While several episodes reference enrollment, site-level statistics, and concomitant statin use [clinical_signal_03_ep_011], [clinical_signal_03_ep_013], [clinical_signal_03_ep_020], there is no direct measurement or description of ALT value trends over time within any subgroup. Therefore, based on the available information, the rate of ALT escalation cannot be determined.",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_b52bd93ffba0435d8f4d69ff",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 744
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_b52bd93ffba0435d8f4d69ff",
              "content": "{\"search_modes\": [\"keyword\", \"semantic\"], \"filter_fields\": [{\"name\": \"scope_id\", \"field_type\": \"string\", \"description\": \"Filter by scope ID\", \"enum_values\": null}, {\"name\": \"start_date\", \"field_type\": \"string\", \"description\": \"Filter episodes after this ISO date\", \"enum_values\": null}, {\"name\": \"end_date\", \"field_type\": \"string\", \"description\": \"Filter episodes before this ISO date\", \"enum_values\": null}], \"max_results_per_search\": 7, \"supports_date_range\": true, \"extra_tools\": [{\"name\": \"batch_retrieve\", \"description\": \"Retrieve multiple full documents by their reference IDs in a single call. PREFER this over calling memory_retrieve multiple times \\u2014 it is far more efficient and uses only one tool call instead of one per document. After memory_search, pass all ref_ids you want to read to this tool.\", \"parameters\": {\"type\": \"object\", \"properties\": {\"ref_ids\": {\"type\": \"array\", \"items\": {\"type\": \"string\"}, \"description\": \"List of reference IDs to retrieve (from search results).\"}}, \"required\": [\"ref_ids\"]}}]}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_3d2932189301421b832427c5",
              "name": "memory_search",
              "arguments": {
                "query": "ALT values escalation in affected subgroup",
                "filters": {}
              }
            }
          ],
          "tokens_used": 1043
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_3d2932189301421b832427c5",
              "content": "[{\"ref_id\": \"clinical_signal_03_ep_011\", \"text\": \"## 2024-05-13 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 189\\n- Active: 182\\n- Screen Failures Cumulative: 27\\n- Withdrawals Cumulative: 7\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 19\\n  - Active: 19\\n  - Statin Concomitant: 5\\n- Site 02\\n  - Enrolled: 14\\n  - Active: 14\\n  - Statin Concomitant: 3\\n- Site 03\\n  - Enrolled: 17\\n  - Active: 17\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 12\\n  - Active: 12\\n  - Statin Concomitant: 3\\n- Site 05\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomita\", \"score\": 0.032266458495966696, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_013\", \"text\": \"## 2024-05-27 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 195\\n- Active: 191\\n- Screen Failures Cumulative: 29\\n- Withdrawals Cumulative: 4\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 19\\n  - Active: 19\\n  - Statin Concomitant: 5\\n- Site 02\\n  - Enrolled: 14\\n  - Active: 14\\n  - Statin Concomitant: 4\\n- Site 03\\n  - Enrolled: 18\\n  - Active: 18\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 13\\n  - Active: 13\\n  - Statin Concomitant: 4\\n- Site 05\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomita\", \"score\": 0.03225806451612903, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_020\", \"text\": \"## 2024-07-15 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 216\\n- Active: 206\\n- Screen Failures Cumulative: 45\\n- Withdrawals Cumulative: 10\\n\\n#### Sites\\n- Site 01 Enrolled: 22\\n- Site 01 Active: 22\\n- Site 01 Statin Concomitant: 7\\n- Site 02 Enrolled: 16\\n- Site 02 Active: 16\\n- Site 02 Statin Concomitant: 5\\n- Site 03 Enrolled: 20\\n- Site 03 Active: 20\\n- Site 03 Statin Concomitant: 6\\n- Site 04 Enrolled: 14\\n- Site 04 Active: 14\\n- Site 04 Statin Concomitant: 4\\n- Site 05 Enrolled: 18\\n- Site\", \"score\": 0.031099324975891997, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"escalation\", \"signal_density\": \"high\"}}, {\"ref_id\": \"clinical_signal_03_ep_010\", \"text\": \"## 2024-05-06 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 184\\n- Active: 182\\n- Screen Failures Cumulative: 20\\n- Withdrawals Cumulative: 2\\n\\n#### Sites\\n- Site 01 Enrolled: 18\\n- Site 01 Active: 18\\n- Site 01 Statin Concomitant: 5\\n- Site 02 Enrolled: 14\\n- Site 02 Active: 14\\n- Site 02 Statin Concomitant: 3\\n- Site 03 Enrolled: 17\\n- Site 03 Active: 17\\n- Site 03 Statin Concomitant: 4\\n- Site 04 Enrolled: 12\\n- Site 04 Active: 12\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 15\\n- Site \", \"score\": 0.031024531024531024, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_012\", \"text\": \"## 2024-05-20 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 192\\n- Active: 186\\n- Screen Failures Cumulative: 21\\n- Withdrawals Cumulative: 6\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 19\\n  - Active: 19\\n  - Statin Concomitant: 5\\n- Site 02\\n  - Enrolled: 14\\n  - Active: 14\\n  - Statin Concomitant: 3\\n- Site 03\\n  - Enrolled: 18\\n  - Active: 18\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 13\\n  - Active: 13\\n  - Statin Concomitant: 3\\n- Site 05\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomita\", \"score\": 0.031009615384615385, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_009\", \"text\": \"## 2024-04-29 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 185\\n- Active: 180\\n- Screen Failures Cumulative: 22\\n- Withdrawals Cumulative: 5\\n\\n#### Sites\\n- Site 01 Enrolled: 18\\n- Site 01 Active: 18\\n- Site 01 Statin Concomitant: 5\\n- Site 02 Enrolled: 14\\n- Site 02 Active: 14\\n- Site 02 Statin Concomitant: 4\\n- Site 03 Enrolled: 17\\n- Site 03 Active: 17\\n- Site 03 Statin Concomitant: 4\\n- Site 04 Enrolled: 12\\n- Site 04 Active: 12\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 15\\n- Site \", \"score\": 0.02967032967032967, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_002\", \"text\": \"## 2024-03-11 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 60\\n- Active: 60\\n- Screen Failures Cumulative: 4\\n- Withdrawals Cumulative: 0\\n\\n#### Sites\\n- Site 01 Enrolled: 6\\n- Site 01 Active: 6\\n- Site 01 Statin Concomitant: 1\\n- Site 02 Enrolled: 4\\n- Site 02 Active: 4\\n- Site 02 Statin Concomitant: 1\\n- Site 03 Enrolled: 5\\n- Site 03 Active: 5\\n- Site 03 Statin Concomitant: 1\\n- Site 04 Enrolled: 4\\n- Site 04 Active: 4\\n- Site 04 Statin Concomitant: 1\\n- Site 05 Enrolled: 5\\n- Site 05 Active: 5\", \"score\": 0.029236022193768675, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_4976fb8942da494789fdee24",
              "name": "memory_search",
              "arguments": {
                "query": "ALT values escalation in affected subgroup with statin use",
                "filters": {}
              }
            }
          ],
          "tokens_used": 3161
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_4976fb8942da494789fdee24",
              "content": "[Context budget exhausted \u2014 synthesize answer from evidence already retrieved]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "The provided documents do not contain specific data on the rate of ALT value escalation in the affected subgroup. While several episodes reference enrollment, site-level statistics, and concomitant statin use [clinical_signal_03_ep_011], [clinical_signal_03_ep_013], [clinical_signal_03_ep_020], there is no direct measurement or description of ALT value trends over time within any subgroup. Therefore, based on the available information, the rate of ALT escalation cannot be determined.",
          "tokens_used": 3294
        }
      ],
      "tool_calls_made": 3,
      "total_tokens": 8242,
      "wall_time_ms": 9472.504614968784,
      "budget_violations": [
        "Cumulative result token limit exceeded: 2697 > 2048"
      ],
      "refs_cited": [
        "clinical_signal_03_ep_011",
        "clinical_signal_03_ep_013",
        "clinical_signal_03_ep_020"
      ]
    },
    "retrieved_ref_ids": [
      "clinical_signal_03_ep_011",
      "clinical_signal_03_ep_013",
      "clinical_signal_03_ep_020"
    ],
    "valid_ref_ids": [
      "clinical_signal_03_ep_011",
      "clinical_signal_03_ep_013",
      "clinical_signal_03_ep_020"
    ]
  },
  {
    "question": {
      "question_id": "cs03_q21_distractor",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 20,
      "question_type": "distractor_resistance",
      "prompt": "Are VAS pain scores or functional assessments correlating with the laboratory abnormalities?",
      "ground_truth": {
        "canonical_answer": "No. Pain endpoints are stable and unrelated to the hepatic safety signal. The ALT elevations correlate with statin co-administration, not pain or functional measures.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_006",
          "clinical_signal_03_ep_017"
        ],
        "key_facts": [
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver",
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q21_distractor",
      "answer_text": "The retrieved documents contain laboratory data (e.g., ALT, AST, bilirubin, creatinine) from the statin subgroup across multiple time points [ref_id: clinical_signal_03_ep_010, ref_id: clinical_signal_03_ep_009, ref_id: clinical_signal_03_ep_011, ref_id: clinical_signal_03_ep_012, ref_id: clinical_signal_03_ep_013, ref_id: clinical_signal_03_ep_008], showing trends such as increasing ALT and AST levels over time. However, none of the documents mention VAS pain scores or functional assessments, nor do they report any correlation analysis between these clinical measures and laboratory abnormalities.\n\nTherefore, based on the available information, there is no evidence to determine whether VAS pain scores or functional assessments correlate with laboratory abnormalities [ref_id: clinical_signal_03_ep_010, ref_id: clinical_signal_03_ep_009, ref_id: clinical_signal_03_ep_011, ref_id: clinical_signal_03_ep_012, ref_id: clinical_signal_03_ep_013, ref_id: clinical_signal_03_ep_008].",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_bcc98990c7aa4b58abfc42c1",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 748
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_bcc98990c7aa4b58abfc42c1",
              "content": "{\"search_modes\": [\"keyword\", \"semantic\"], \"filter_fields\": [{\"name\": \"scope_id\", \"field_type\": \"string\", \"description\": \"Filter by scope ID\", \"enum_values\": null}, {\"name\": \"start_date\", \"field_type\": \"string\", \"description\": \"Filter episodes after this ISO date\", \"enum_values\": null}, {\"name\": \"end_date\", \"field_type\": \"string\", \"description\": \"Filter episodes before this ISO date\", \"enum_values\": null}], \"max_results_per_search\": 7, \"supports_date_range\": true, \"extra_tools\": [{\"name\": \"batch_retrieve\", \"description\": \"Retrieve multiple full documents by their reference IDs in a single call. PREFER this over calling memory_retrieve multiple times \\u2014 it is far more efficient and uses only one tool call instead of one per document. After memory_search, pass all ref_ids you want to read to this tool.\", \"parameters\": {\"type\": \"object\", \"properties\": {\"ref_ids\": {\"type\": \"array\", \"items\": {\"type\": \"string\"}, \"description\": \"List of reference IDs to retrieve (from search results).\"}}, \"required\": [\"ref_ids\"]}}]}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_641930216bdf4e328aa19d52",
              "name": "memory_search",
              "arguments": {
                "query": "VAS pain scores correlation with laboratory abnormalities"
              }
            }
          ],
          "tokens_used": 1042
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_641930216bdf4e328aa19d52",
              "content": "[{\"ref_id\": \"clinical_signal_03_ep_010\", \"text\": \"## 2024-05-06 Daily Operations Summary\\n### Lab Panels\\n#### Statin Subgroup\\n- N: 54\\n- ALT (U/L) Mean: 37.2\\n- ALT (U/L) Median: 35.2\\n- AST (U/L) Mean: 32.1\\n- AST (U/L) Median: 30.9\\n- Bilirubin (mg/dL) Mean: 0.68\\n- Bilirubin (mg/dL) Median: 0.65\\n- ALP (U/L) Mean: 65.1\\n- ALP (U/L) Median: 62.3\\n- Creatinine (mg/dL) Mean: 1.09\\n- Creatinine (mg/dL) Median: 0.88\\n- BUN (mg/dL) Mean: 17.8\\n- BUN (mg/dL) Median: 16.4\\n- WBC (K/\\u00b5L) Mean: 6.3\\n- WBC (K/\\u00b5L) Median: 6.7\\n- Platelets (K/\\u00b5L) Mean: 245\\n- Platelets (K\", \"score\": 0.031544957774465976, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_009\", \"text\": \"## 2024-04-29 Daily Operations Summary\\n### Lab Panels\\n#### Statin Subgroup\\n- N: 54\\n- ALT (U/L) Mean: 32.3\\n- ALT (U/L) Median: 31.9\\n- AST (U/L) Mean: 31.2\\n- AST (U/L) Median: 31.2\\n- Bilirubin (mg/dL) Mean: 0.56\\n- Bilirubin (mg/dL) Median: 0.56\\n- ALP (U/L) Mean: 66.5\\n- ALP (U/L) Median: 70.2\\n- Creatinine (mg/dL) Mean: 0.96\\n- Creatinine (mg/dL) Median: 0.83\\n- BUN (mg/dL) Mean: 17.3\\n- BUN (mg/dL) Median: 11.3\\n- WBC (K) Mean: 6.9\\n- WBC (K) Median: 7.6\\n- Platelets (K) Mean: 238\\n- Platelets (K) Median:\", \"score\": 0.03128054740957967, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_018\", \"text\": \"## 2024-07-01 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 210\\n- Active: 204\\n- Screen Failures Cumulative: 53\\n- Withdrawals Cumulative: 6\\n\\n#### Sites\\n- Site 01 Enrolled: 21\\n- Site 01 Active: 21\\n- Site 01 Statin Concomitant: 7\\n- Site 02 Enrolled: 16\\n- Site 02 Active: 16\\n- Site 02 Statin Concomitant: 4\\n- Site 03 Enrolled: 19\\n- Site 03 Active: 19\\n- Site 03 Statin Concomitant: 5\\n- Site 04 Enrolled: 14\\n- Site 04 Active: 14\\n- Site 04 Statin Concomitant: 4\\n- Site 05 Enrolled: 17\\n- Site \", \"score\": 0.031099324975891997, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"escalation\", \"signal_density\": \"high\"}}, {\"ref_id\": \"clinical_signal_03_ep_011\", \"text\": \"## 2024-05-13 Daily Operations Summary\\n### Lab Panels\\n#### Statin Subgroup\\n- N: 55\\n- ALT (U/L) Mean: 47.6\\n- ALT (U/L) Median: 47.4\\n- AST (U/L) Mean: 35.8\\n- AST (U/L) Median: 34.3\\n- Bilirubin (mg/dL) Mean: 0.7\\n- Bilirubin (mg/dL) Median: 0.67\\n- ALP (U/L) Mean: 67.5\\n- ALP (U/L) Median: 61.8\\n- Creatinine (mg/dL) Mean: 0.8\\n- Creatinine (mg/dL) Median: 0.86\\n- BUN (mg/dL) Mean: 13.5\\n- BUN (mg/dL) Median: 15.1\\n- WBC (K) Mean: 6.7\\n- WBC (K) Median: 5.6\\n- Platelets (K) Mean: 258\\n- Platelets (K) Median: 2\", \"score\": 0.031024531024531024, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_012\", \"text\": \"## 2024-05-20 Daily Operations Summary\\n### Lab Panels\\n- Statin Subgroup\\n  - N: 51\\n  - ALT (U/L) Mean: 47.2\\n  - ALT (U/L) Median: 45.7\\n  - AST (U/L) Mean: 41.0\\n  - AST (U/L) Median: 41.0\\n  - Bilirubin (mg/dL) Mean: 0.73\\n  - Bilirubin (mg/dL) Median: 0.72\\n  - ALP (U/L) Mean: 61.9\\n  - ALP (U/L) Median: 56.0\\n  - Creatinine (mg/dL) Mean: 1.07\\n  - Creatinine (mg/dL) Median: 0.92\\n  - BUN (mg/dL) Mean: 16.8\\n  - BUN (mg/dL) Median: 15.4\\n  - WBC (K) Mean: 7.7\\n  - WBC (K) Median: 7.1\\n  - Platelets (K) Mean\", \"score\": 0.030776515151515152, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_013\", \"text\": \"## 2024-05-27 Daily Operations Summary\\n### Lab Panels\\n#### Statin Subgroup\\n- N: 52\\n- ALT (U/L) Mean: 52.4\\n- ALT (U/L) Median: 50.8\\n- AST (U/L) Mean: 45.0\\n- AST (U/L) Median: 44.3\\n- Bilirubin (mg/dL) Mean: 0.84\\n- Bilirubin (mg/dL) Median: 0.82\\n- ALP (U/L) Mean: 63.5\\n- ALP (U/L) Median: 55.7\\n- Creatinine (mg/dL) Mean: 0.83\\n- Creatinine (mg/dL) Median: 0.85\\n- BUN (mg/dL) Mean: 17.5\\n- BUN (mg/dL) Median: 12.2\\n- WBC (K) Mean: 8.4\\n- WBC (K) Median: 5.7\\n- Platelets (K) Mean: 238\\n- Platelets (K) Median:\", \"score\": 0.030536130536130537, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_008\", \"text\": \"## 2024-04-22 Daily Operations Summary\\n### Lab Panels\\n#### Statin Subgroup\\n- N: 52\\n- ALT (U/L) Mean: 25.0\\n- ALT (U/L) Median: 22.3\\n- AST (U/L) Mean: 20.6\\n- AST (U/L) Median: 19.0\\n- Bilirubin (mg/dL) Mean: 0.73\\n- Bilirubin (mg/dL) Median: 0.7\\n- ALP (U/L) Mean: 73.1\\n- ALP (U/L) Median: 76.4\\n- Creatinine (mg/dL) Mean: 0.81\\n- Creatinine (mg/dL) Median: 0.83\\n- BUN (mg/dL) Mean: 15.6\\n- BUN (mg/dL) Median: 12.5\\n- WBC (K) Mean: 6.0\\n- WBC (K) Median: 6.3\\n- Platelets (K) Mean: 242\\n- Platelets (K) Median: \", \"score\": 0.030303030303030304, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_35055d8abc514e88a015cf17",
              "name": "memory_search",
              "arguments": {
                "query": "functional assessments correlation with laboratory abnormalities"
              }
            }
          ],
          "tokens_used": 3412
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_35055d8abc514e88a015cf17",
              "content": "[Context budget exhausted \u2014 synthesize answer from evidence already retrieved]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "The retrieved documents contain laboratory data (e.g., ALT, AST, bilirubin, creatinine) from the statin subgroup across multiple time points [ref_id: clinical_signal_03_ep_010, ref_id: clinical_signal_03_ep_009, ref_id: clinical_signal_03_ep_011, ref_id: clinical_signal_03_ep_012, ref_id: clinical_signal_03_ep_013, ref_id: clinical_signal_03_ep_008], showing trends such as increasing ALT and AST levels over time. However, none of the documents mention VAS pain scores or functional assessments, nor do they report any correlation analysis between these clinical measures and laboratory abnormalities.\n\nTherefore, based on the available information, there is no evidence to determine whether VAS pain scores or functional assessments correlate with laboratory abnormalities [ref_id: clinical_signal_03_ep_010, ref_id: clinical_signal_03_ep_009, ref_id: clinical_signal_03_ep_011, ref_id: clinical_signal_03_ep_012, ref_id: clinical_signal_03_ep_013, ref_id: clinical_signal_03_ep_008].",
          "tokens_used": 3707
        }
      ],
      "tool_calls_made": 3,
      "total_tokens": 8909,
      "wall_time_ms": 14501.53756106738,
      "budget_violations": [
        "Cumulative result token limit exceeded: 2685 > 2048"
      ],
      "refs_cited": []
    },
    "retrieved_ref_ids": [],
    "valid_ref_ids": []
  },
  {
    "question": {
      "question_id": "cs03_q22_counterfactual",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 20,
      "question_type": "counterfactual",
      "prompt": "If the ALT elevations were caused by a viral hepatitis outbreak among trial subjects, what pattern would you expect? Does the data match?",
      "ground_truth": {
        "canonical_answer": "Viral hepatitis would show clustered onset at specific sites, associated symptoms (fatigue, jaundice), and positive viral serologies. Instead, the elevations are distributed across sites and correlate with statin co-administration, not geography or viral exposure. The pattern is consistent with a pharmacokinetic interaction, not infection.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_018",
          "clinical_signal_03_ep_019"
        ],
        "key_facts": [
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event",
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge",
          "the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns",
          "Site 07 lab equipment issue is not the cause of ALT elevations",
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver",
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q22_counterfactual",
      "answer_text": "The provided documents do not contain specific information about ALT elevation patterns associated with a viral hepatitis outbreak or whether the observed data matches such a pattern. The documents are daily operations summaries that report enrollment numbers, site-level participation, and concomitant medication use (e.g., statins), but they lack liver function test data, temporal patterns of ALT elevations, or virological testing results that would be necessary to assess a potential hepatitis outbreak [clinical_signal_03_ep_013][clinical_signal_03_ep_011][clinical_signal_03_ep_010]. \n\nIn general, a viral hepatitis outbreak in a clinical trial would present with clustered, temporally related ALT elevations across multiple sites or regions, often with symptoms of acute hepatitis (e.g., jaundice, fatigue) and positive serological markers (e.g., HAV IgM, HBsAg, HCV RNA). The data currently available does not confirm or rule out such a pattern due to insufficient detail [ref_needed].\n\nTherefore, based on the retrieved information, it is not possible to determine whether the ALT elevations follow a pattern consistent with a viral hepatitis outbreak.",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_97ba25288ad3498eb3beeaa3",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 763
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_97ba25288ad3498eb3beeaa3",
              "content": "{\"search_modes\": [\"keyword\", \"semantic\"], \"filter_fields\": [{\"name\": \"scope_id\", \"field_type\": \"string\", \"description\": \"Filter by scope ID\", \"enum_values\": null}, {\"name\": \"start_date\", \"field_type\": \"string\", \"description\": \"Filter episodes after this ISO date\", \"enum_values\": null}, {\"name\": \"end_date\", \"field_type\": \"string\", \"description\": \"Filter episodes before this ISO date\", \"enum_values\": null}], \"max_results_per_search\": 7, \"supports_date_range\": true, \"extra_tools\": [{\"name\": \"batch_retrieve\", \"description\": \"Retrieve multiple full documents by their reference IDs in a single call. PREFER this over calling memory_retrieve multiple times \\u2014 it is far more efficient and uses only one tool call instead of one per document. After memory_search, pass all ref_ids you want to read to this tool.\", \"parameters\": {\"type\": \"object\", \"properties\": {\"ref_ids\": {\"type\": \"array\", \"items\": {\"type\": \"string\"}, \"description\": \"List of reference IDs to retrieve (from search results).\"}}, \"required\": [\"ref_ids\"]}}]}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_be269df3ab424466be0b146a",
              "name": "memory_search",
              "arguments": {
                "query": "ALT elevations pattern viral hepatitis outbreak trial subjects",
                "search_mode": "semantic"
              }
            }
          ],
          "tokens_used": 1063
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_be269df3ab424466be0b146a",
              "content": "[{\"ref_id\": \"clinical_signal_03_ep_013\", \"text\": \"## 2024-05-27 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 195\\n- Active: 191\\n- Screen Failures Cumulative: 29\\n- Withdrawals Cumulative: 4\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 19\\n  - Active: 19\\n  - Statin Concomitant: 5\\n- Site 02\\n  - Enrolled: 14\\n  - Active: 14\\n  - Statin Concomitant: 4\\n- Site 03\\n  - Enrolled: 18\\n  - Active: 18\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 13\\n  - Active: 13\\n  - Statin Concomitant: 4\\n- Site 05\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomita\", \"score\": 0.03252247488101534, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_011\", \"text\": \"## 2024-05-13 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 189\\n- Active: 182\\n- Screen Failures Cumulative: 27\\n- Withdrawals Cumulative: 7\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 19\\n  - Active: 19\\n  - Statin Concomitant: 5\\n- Site 02\\n  - Enrolled: 14\\n  - Active: 14\\n  - Statin Concomitant: 3\\n- Site 03\\n  - Enrolled: 17\\n  - Active: 17\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 12\\n  - Active: 12\\n  - Statin Concomitant: 3\\n- Site 05\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomita\", \"score\": 0.031754032258064516, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_010\", \"text\": \"## 2024-05-06 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 184\\n- Active: 182\\n- Screen Failures Cumulative: 20\\n- Withdrawals Cumulative: 2\\n\\n#### Sites\\n- Site 01 Enrolled: 18\\n- Site 01 Active: 18\\n- Site 01 Statin Concomitant: 5\\n- Site 02 Enrolled: 14\\n- Site 02 Active: 14\\n- Site 02 Statin Concomitant: 3\\n- Site 03 Enrolled: 17\\n- Site 03 Active: 17\\n- Site 03 Statin Concomitant: 4\\n- Site 04 Enrolled: 12\\n- Site 04 Active: 12\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 15\\n- Site \", \"score\": 0.03149801587301587, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_020\", \"text\": \"## 2024-07-15 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 216\\n- Active: 206\\n- Screen Failures Cumulative: 45\\n- Withdrawals Cumulative: 10\\n\\n#### Sites\\n- Site 01 Enrolled: 22\\n- Site 01 Active: 22\\n- Site 01 Statin Concomitant: 7\\n- Site 02 Enrolled: 16\\n- Site 02 Active: 16\\n- Site 02 Statin Concomitant: 5\\n- Site 03 Enrolled: 20\\n- Site 03 Active: 20\\n- Site 03 Statin Concomitant: 6\\n- Site 04 Enrolled: 14\\n- Site 04 Active: 14\\n- Site 04 Statin Concomitant: 4\\n- Site 05 Enrolled: 18\\n- Site\", \"score\": 0.030536130536130537, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"escalation\", \"signal_density\": \"high\"}}, {\"ref_id\": \"clinical_signal_03_ep_012\", \"text\": \"## 2024-05-20 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 192\\n- Active: 186\\n- Screen Failures Cumulative: 21\\n- Withdrawals Cumulative: 6\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 19\\n  - Active: 19\\n  - Statin Concomitant: 5\\n- Site 02\\n  - Enrolled: 14\\n  - Active: 14\\n  - Statin Concomitant: 3\\n- Site 03\\n  - Enrolled: 18\\n  - Active: 18\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 13\\n  - Active: 13\\n  - Statin Concomitant: 3\\n- Site 05\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomita\", \"score\": 0.030536130536130537, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_014\", \"text\": \"## 2024-06-03 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 192\\n- Active: 182\\n- Screen Failures Cumulative: 28\\n- Withdrawals Cumulative: 10\\n\\n#### Sites\\n- Site 01 Enrolled: 19\\n- Site 01 Active: 19\\n- Site 01 Statin Concomitant: 5\\n- Site 02 Enrolled: 14\\n- Site 02 Active: 14\\n- Site 02 Statin Concomitant: 4\\n- Site 03 Enrolled: 18\\n- Site 03 Active: 18\\n- Site 03 Statin Concomitant: 4\\n- Site 04 Enrolled: 13\\n- Site 04 Active: 13\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 16\\n- Site\", \"score\": 0.03047794966520434, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_009\", \"text\": \"## 2024-04-29 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 185\\n- Active: 180\\n- Screen Failures Cumulative: 22\\n- Withdrawals Cumulative: 5\\n\\n#### Sites\\n- Site 01 Enrolled: 18\\n- Site 01 Active: 18\\n- Site 01 Statin Concomitant: 5\\n- Site 02 Enrolled: 14\\n- Site 02 Active: 14\\n- Site 02 Statin Concomitant: 4\\n- Site 03 Enrolled: 17\\n- Site 03 Active: 17\\n- Site 03 Statin Concomitant: 4\\n- Site 04 Enrolled: 12\\n- Site 04 Active: 12\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 15\\n- Site \", \"score\": 0.030158730158730156, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_b47aee152050423c9b578f1b",
              "name": "memory_search",
              "arguments": {
                "query": "ALT elevations viral hepatitis pattern in clinical trial",
                "search_mode": "semantic"
              }
            }
          ],
          "tokens_used": 3187
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_b47aee152050423c9b578f1b",
              "content": "[Context budget exhausted \u2014 synthesize answer from evidence already retrieved]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "The provided documents do not contain specific information about ALT elevation patterns associated with a viral hepatitis outbreak or whether the observed data matches such a pattern. The documents are daily operations summaries that report enrollment numbers, site-level participation, and concomitant medication use (e.g., statins), but they lack liver function test data, temporal patterns of ALT elevations, or virological testing results that would be necessary to assess a potential hepatitis outbreak [clinical_signal_03_ep_013][clinical_signal_03_ep_011][clinical_signal_03_ep_010]. \n\nIn general, a viral hepatitis outbreak in a clinical trial would present with clustered, temporally related ALT elevations across multiple sites or regions, often with symptoms of acute hepatitis (e.g., jaundice, fatigue) and positive serological markers (e.g., HAV IgM, HBsAg, HCV RNA). The data currently available does not confirm or rule out such a pattern due to insufficient detail [ref_needed].\n\nTherefore, based on the retrieved information, it is not possible to determine whether the ALT elevations follow a pattern consistent with a viral hepatitis outbreak.",
          "tokens_used": 3451
        }
      ],
      "tool_calls_made": 3,
      "total_tokens": 8464,
      "wall_time_ms": 10103.980530053377,
      "budget_violations": [
        "Cumulative result token limit exceeded: 2700 > 2048"
      ],
      "refs_cited": [
        "clinical_signal_03_ep_013",
        "clinical_signal_03_ep_011",
        "clinical_signal_03_ep_010"
      ]
    },
    "retrieved_ref_ids": [
      "clinical_signal_03_ep_013",
      "clinical_signal_03_ep_011",
      "clinical_signal_03_ep_010"
    ],
    "valid_ref_ids": [
      "clinical_signal_03_ep_013",
      "clinical_signal_03_ep_011",
      "clinical_signal_03_ep_010"
    ]
  },
  {
    "question": {
      "question_id": "cs03_q23_null",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 20,
      "question_type": "null_hypothesis",
      "prompt": "How many protocol deviations were reported at Site 03 in the most recent weekly summary?",
      "ground_truth": {
        "canonical_answer": "The protocol deviation count as documented in the weekly site summary.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_018"
        ],
        "key_facts": []
      }
    },
    "answer": {
      "question_id": "cs03_q23_null",
      "answer_text": "The provided documents do not contain any weekly summaries explicitly mentioning protocol deviations for Site 03. The retrieved results are daily operations summaries that report enrollment and concomitant medication data but do not include information on protocol deviations [clinical_signal_03_ep_014][clinical_signal_03_ep_005][clinical_signal_03_ep_003][clinical_signal_03_ep_009][clinical_signal_03_ep_007][clinical_signal_03_ep_006][clinical_signal_03_ep_016]. \n\nTherefore, based on the available information, the number of protocol deviations reported at Site 03 in the most recent weekly summary cannot be determined.",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_4d0a3925066346a2bcd2b157",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 751
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_4d0a3925066346a2bcd2b157",
              "content": "{\"search_modes\": [\"keyword\", \"semantic\"], \"filter_fields\": [{\"name\": \"scope_id\", \"field_type\": \"string\", \"description\": \"Filter by scope ID\", \"enum_values\": null}, {\"name\": \"start_date\", \"field_type\": \"string\", \"description\": \"Filter episodes after this ISO date\", \"enum_values\": null}, {\"name\": \"end_date\", \"field_type\": \"string\", \"description\": \"Filter episodes before this ISO date\", \"enum_values\": null}], \"max_results_per_search\": 7, \"supports_date_range\": true, \"extra_tools\": [{\"name\": \"batch_retrieve\", \"description\": \"Retrieve multiple full documents by their reference IDs in a single call. PREFER this over calling memory_retrieve multiple times \\u2014 it is far more efficient and uses only one tool call instead of one per document. After memory_search, pass all ref_ids you want to read to this tool.\", \"parameters\": {\"type\": \"object\", \"properties\": {\"ref_ids\": {\"type\": \"array\", \"items\": {\"type\": \"string\"}, \"description\": \"List of reference IDs to retrieve (from search results).\"}}, \"required\": [\"ref_ids\"]}}]}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_a33f3887ab2d45f1a13670c2",
              "name": "memory_search",
              "arguments": {
                "query": "Site 03 protocol deviations weekly summary",
                "filters": {
                  "scope_id": "Site 03"
                },
                "limit": 7
              }
            }
          ],
          "tokens_used": 1065
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_a33f3887ab2d45f1a13670c2",
              "content": "[]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_5fc0990d5f39453aa52e6e2a",
              "name": "memory_search",
              "arguments": {
                "query": "protocol deviations Site 03 weekly summary",
                "limit": 7
              }
            }
          ],
          "tokens_used": 1111
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_5fc0990d5f39453aa52e6e2a",
              "content": "[{\"ref_id\": \"clinical_signal_03_ep_014\", \"text\": \"## 2024-06-03 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 192\\n- Active: 182\\n- Screen Failures Cumulative: 28\\n- Withdrawals Cumulative: 10\\n\\n#### Sites\\n- Site 01 Enrolled: 19\\n- Site 01 Active: 19\\n- Site 01 Statin Concomitant: 5\\n- Site 02 Enrolled: 14\\n- Site 02 Active: 14\\n- Site 02 Statin Concomitant: 4\\n- Site 03 Enrolled: 18\\n- Site 03 Active: 18\\n- Site 03 Statin Concomitant: 4\\n- Site 04 Enrolled: 13\\n- Site 04 Active: 13\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 16\\n- Site\", \"score\": 0.03125763125763126, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_005\", \"text\": \"## 2024-04-01 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 120\\n- Active: 118\\n- Screen Failures Cumulative: 11\\n- Withdrawals Cumulative: 2\\n\\n#### Sites\\n- Site 01 Enrolled: 12\\n- Site 01 Active: 12\\n- Site 01 Statin Concomitant: 4\\n- Site 02 Enrolled: 9\\n- Site 02 Active: 9\\n- Site 02 Statin Concomitant: 3\\n- Site 03 Enrolled: 11\\n- Site 03 Active: 11\\n- Site 03 Statin Concomitant: 3\\n- Site 04 Enrolled: 8\\n- Site 04 Active: 8\\n- Site 04 Statin Concomitant: 2\\n- Site 05 Enrolled: 10\\n- Site 05 A\", \"score\": 0.030886196246139225, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_003\", \"text\": \"## 2024-03-18 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 80\\n- Active: 80\\n- Screen Failures Cumulative: 5\\n- Withdrawals Cumulative: 0\\n\\n#### Sites\\n- Site 01 Enrolled: 8\\n- Site 01 Active: 8\\n- Site 01 Statin Concomitant: 2\\n- Site 02 Enrolled: 6\\n- Site 02 Active: 6\\n- Site 02 Statin Concomitant: 1\\n- Site 03 Enrolled: 7\\n- Site 03 Active: 7\\n- Site 03 Statin Concomitant: 1\\n- Site 04 Enrolled: 5\\n- Site 04 Active: 5\\n- Site 04 Statin Concomitant: 1\\n- Site 05 Enrolled: 6\\n- Site 05 Active: 6\", \"score\": 0.030776515151515152, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_009\", \"text\": \"## 2024-04-29 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 185\\n- Active: 180\\n- Screen Failures Cumulative: 22\\n- Withdrawals Cumulative: 5\\n\\n#### Sites\\n- Site 01 Enrolled: 18\\n- Site 01 Active: 18\\n- Site 01 Statin Concomitant: 5\\n- Site 02 Enrolled: 14\\n- Site 02 Active: 14\\n- Site 02 Statin Concomitant: 4\\n- Site 03 Enrolled: 17\\n- Site 03 Active: 17\\n- Site 03 Statin Concomitant: 4\\n- Site 04 Enrolled: 12\\n- Site 04 Active: 12\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 15\\n- Site \", \"score\": 0.03036576949620428, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_007\", \"text\": \"## 2024-04-15 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 160\\n- Active: 156\\n- Screen Failures Cumulative: 15\\n- Withdrawals Cumulative: 4\\n\\n#### Sites\\n- Site 01 Enrolled: 16\\n- Site 01 Active: 16\\n- Site 01 Statin Concomitant: 4\\n- Site 02 Enrolled: 12\\n- Site 02 Active: 12\\n- Site 02 Statin Concomitant: 3\\n- Site 03 Enrolled: 15\\n- Site 03 Active: 15\\n- Site 03 Statin Concomitant: 4\\n- Site 04 Enrolled: 10\\n- Site 04 Active: 10\\n- Site 04 Statin Concomitant: 2\\n- Site 05 Enrolled: 13\\n- Site \", \"score\": 0.030090497737556562, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_006\", \"text\": \"## 2024-04-08 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 140\\n- Active: 137\\n- Screen Failures Cumulative: 11\\n- Withdrawals Cumulative: 3\\n\\n#### Sites\\n- Site 01 Enrolled: 14\\n- Site 01 Active: 14\\n- Site 01 Statin Concomitant: 4\\n- Site 02 Enrolled: 10\\n- Site 02 Active: 10\\n- Site 02 Statin Concomitant: 3\\n- Site 03 Enrolled: 18\\n- Site 03 Active: 17\\n- Site 03 Statin Concomitant: 5\\n- Site 04 Enrolled: 9\\n- Site 04 Active: 9\\n- Site 04 Statin Concomitant: 2\\n- Site 05 Enrolled: 11\\n- Site 05\", \"score\": 0.029437229437229435, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_016\", \"text\": \"## 2024-06-17 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 204\\n- Active: 198\\n- Screen Failures Cumulative: 47\\n- Withdrawals Cumulative: 6\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 20\\n  - Active: 20\\n  - Statin Concomitant: 6\\n- Site 02\\n  - Enrolled: 15\\n  - Active: 15\\n  - Statin Concomitant: 4\\n- Site 03\\n  - Enrolled: 19\\n  - Active: 19\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 13\\n  - Active: 13\\n  - Statin Concomitant: 4\\n- Site 05\\n  - Enrolled: 17\\n  - Active: 17\\n  - Statin Concomita\", \"score\": 0.02928692699490662, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"red_herring\", \"signal_density\": \"medium\"}}]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_50e63d5da58c4b0981b5879f",
              "name": "memory_search",
              "arguments": {
                "query": "weekly summary Site 03 protocol deviations",
                "limit": 7
              }
            }
          ],
          "tokens_used": 3217
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_50e63d5da58c4b0981b5879f",
              "content": "[Context budget exhausted \u2014 synthesize answer from evidence already retrieved]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "The provided documents do not contain any weekly summaries explicitly mentioning protocol deviations for Site 03. The retrieved results are daily operations summaries that report enrollment and concomitant medication data but do not include information on protocol deviations [clinical_signal_03_ep_014][clinical_signal_03_ep_005][clinical_signal_03_ep_003][clinical_signal_03_ep_009][clinical_signal_03_ep_007][clinical_signal_03_ep_006][clinical_signal_03_ep_016]. \n\nTherefore, based on the available information, the number of protocol deviations reported at Site 03 in the most recent weekly summary cannot be determined.",
          "tokens_used": 3394
        }
      ],
      "tool_calls_made": 4,
      "total_tokens": 9538,
      "wall_time_ms": 11356.91655590199,
      "budget_violations": [
        "Cumulative result token limit exceeded: 2690 > 2048"
      ],
      "refs_cited": [
        "clinical_signal_03_ep_014",
        "clinical_signal_03_ep_005",
        "clinical_signal_03_ep_003",
        "clinical_signal_03_ep_009",
        "clinical_signal_03_ep_007",
        "clinical_signal_03_ep_006",
        "clinical_signal_03_ep_016"
      ]
    },
    "retrieved_ref_ids": [
      "clinical_signal_03_ep_014",
      "clinical_signal_03_ep_005",
      "clinical_signal_03_ep_003",
      "clinical_signal_03_ep_009",
      "clinical_signal_03_ep_007",
      "clinical_signal_03_ep_006",
      "clinical_signal_03_ep_016"
    ],
    "valid_ref_ids": [
      "clinical_signal_03_ep_014",
      "clinical_signal_03_ep_005",
      "clinical_signal_03_ep_003",
      "clinical_signal_03_ep_009",
      "clinical_signal_03_ep_007",
      "clinical_signal_03_ep_006",
      "clinical_signal_03_ep_016"
    ]
  }
]